Skip to main content
. Author manuscript; available in PMC: 2019 Sep 20.
Published in final edited form as: Arthritis Rheumatol. 2019 Aug 6;71(9):1450–1459. doi: 10.1002/art.40911

Figure 2.

Figure 2.

Multivariable analyses of associations between baseline variables and the occurrence of MACE during tofacitinib treatment

For all continuous variables, unit = 1 unless specified; in unit = x, ‘x’ is the change in the continuous variable corresponding to which the change in hazards is observed. Only variables with significant associations with occurrence of MACE are shown; this analysis also included baseline BMI and time-varying tofacitinib dose (both not significant).

CI = confidence interval; HDL-c = high-density lipoprotein cholesterol; HR = hazard ratio; MACE = major adverse cardiovascular event; n = number of patients with future MACE for each baseline variable; N = number of patients included in the analysis for each baseline variable; TC = total cholesterol